ReviewInternational journal of oncology2016
Human telomerase reverse transcriptase regulation by DNA methylation, transcription factor binding and alternative splicing (Review).
Review in International journal of oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 41 citations in OpenAlex.
- Extended longevity of termite kings and queens is accompanied by extranuclear localization of telomerase in somatic organs and caste-specific expression of its isoforms.Insect science · 2025Article
- RNA binding proteins (RBPs) on genetic stability and diseases.Global medical genetics · 2025Review
- Leukocyte telomere length and telomerase activity in Long COVID patients from Rio de Janeiro, Brazil.Memorias do Instituto Oswaldo Cruz · 2025Article
- Article
- THOR is a targetable epigenetic biomarker with clinical implications in breast cancer.Clinical epigenetics · 2022Article
- Review
- Noncanonical Role of Telomerase in Regulation of Microvascular Redox Environment With Implications for Coronary Artery Disease.Function (Oxford, England) · 2022Article
- Intron 4-5 hTERT DNA Hypermethylation in Merkel Cell Carcinoma: Frequency, Association with Other Clinico-pathological Features and Prognostic Relevance.Endocrine pathology · 2021Article
- Characterization of TERT and BRAF copy number variation in papillary thyroid carcinoma: An analysis of the cancer genome atlas study.Genes, chromosomes & cancer · 2021Article
- Long-lived termite kings and queens activate telomerase in somatic organs.Proceedings. Biological sciences · 2021Article
- Allele-specific proximal promoter hypomethylation of the telomerase reverse transcriptase gene (TERT) associates with TERT expression in multiple cancers.Molecular oncology · 2020Article
- Characterization of Allele-Specific Regulation of Telomerase Reverse Transcriptase in Promoter Mutant Thyroid Cancer Cell Lines.Thyroid : official journal of the American Thyroid Association · 2020Article
- Article
- Measuring biological aging in humans: A quest.Aging cell · 2020Review
- Vital and Distinct Roles of H2A.Z Isoforms in Hepatocellular Carcinoma.OncoTargets and therapy · 2020Article
- Telomerase Biology Associations Offer Keys to Cancer and Aging Therapeutics.Current aging science · 2020Review
- Telomere-related Markers for Cancer.Current topics in medicinal chemistry · 2020Review
- Telomerase Reverse Transcriptase (TERT) Regulation in Thyroid Cancer: A Review.Frontiers in endocrinology · 2020Review
- Expression and regulation of telomerase in human T cell differentiation, activation, aging and diseases.Cellular immunology · 2019Review
- Profiling of prognostic alternative splicing in melanoma.Oncology letters · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
The catalytic subunit of telomerase, human telomerase reverse transcriptase (hTERT), plays an essential role in telomere maintenance to oppose cellular senescence and, is highly regulated in normal and cancerous cells. Regulation of hTERT occurs through multiple avenues, including a unique pattern of CpG promoter methylation and alternative splicing. Promoter methylation affects the binding of transcription factors, resulting in changes in expression of the gene. In addition to expression level changes, changes in promoter binding can affect alternative splicing in a cotranscriptional manner. The alternative splicing of hTERT results in either the full length transcript which can form the active telomerase complex with hTR, or numerous inactive isoforms. Both regulation strategies are exploited in cancer to activate telomerase, however, the exact mechanism is unknown. Therefore, unraveling the link between promoter methylation status and alternative splicing for hTERT could expose yet another level of hTERT regulation. In an attempt to provide insight into the cellular control of active telomerase in cancer, this review will discuss our current perspective on CpG methylation of the hTERT promoter region, summarize the different forms of alternatively spliced variants, and examine examples of transcription factor binding that affects splicing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.